Zacks Investment ResearchThu, 26 Mar 2026 16:06:10 GMTALT Stock and the 2026 MASH Race: Dual Agonists vs. New MechanismsALT-0.28%
Zacks Investment ResearchThu, 26 Mar 2026 14:43:07 GMTAltimmune Stock: Neutral Outlook With Big 2026 CatalystsALT-0.28%
Zacks Investment ResearchThu, 26 Mar 2026 14:26:11 GMTALT Pemvidutide Explained: What Makes It Different in MASHALT-0.28%
Seeking AlphaThu, 05 Mar 2026 19:15:56 GMTAltimmune, Inc. (ALT) Q4 2025 Earnings Call TranscriptALT-0.28%
BenzingaWed, 28 Jan 2026 21:13:03 GMTAltimmune (ALT) Shares Slide On $75 Million Stock OfferingALT-0.28%
24/7 Wall StreetFri, 23 Jan 2026 19:06:34 GMTInvestor Bets $100k On David v Goliath Matchup With Altimmune and Eli LillyALT-0.28%